Ascelia Pharma AB
STO:ACE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascelia Pharma AB
STO:ACE
|
SE |
|
C
|
Chayo Group PCL
SET:CHAYO
|
TH |
|
A
|
Aksharchem (India) Ltd
NSE:AKSHARCHEM
|
IN |
|
A
|
Alps Industries Ltd
NSE:ALPSINDUS
|
IN |
|
P
|
PC Direct Inc
KOSDAQ:051380
|
KR |
|
Amerisafe Inc
NASDAQ:AMSF
|
US |
|
A
|
Aspo Oyj
OMXH:ASPO
|
FI |
|
Suominen Oyj
LSE:0M1M
|
FI |
|
M
|
Moorim SP Co Ltd
KOSDAQ:001810
|
KR |
Ascelia Pharma AB
Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.
Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
